Detalles de la búsqueda
1.
Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting.
J Am Pharm Assoc (2003);
63(1): 188-192, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36243653
2.
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
BMC Pulm Med;
21(1): 253, 2021 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34332555
3.
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Health Qual Life Outcomes;
15(1): 128, 2017 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28637460
4.
Early genetic testing in pediatric epilepsy: Diagnostic and cost implications.
Epilepsia Open;
9(1): 439-444, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38071479
5.
A real-world comparative assessment of complications following various mid-urethral sling procedures for the treatment of stress urinary incontinence.
J Long Term Eff Med Implants;
22(4): 329-40, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23662664
6.
Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
Int J Chron Obstruct Pulmon Dis;
17: 593-608, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35342290
7.
Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient Population.
J Pers Med;
12(12)2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36556194
8.
Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer.
JAMA Netw Open;
5(10): e2238167, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36279135
9.
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice.
JAMA Neurol;
79(12): 1267-1276, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36315135
10.
Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-Related Exacerbations.
Int J Chron Obstruct Pulmon Dis;
16: 2755-2767, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34675501
11.
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
Pulm Ther;
7(1): 203-219, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728597
12.
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Int J Chron Obstruct Pulmon Dis;
16: 1149-1161, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33911860
13.
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study.
J Pers Med;
11(11)2021 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34834543
14.
Incremental Costs Associated with Length of Hospitalization Due to Viral Pneumonia: Impact of Intensive Care and Economic Implications of Reducing the Length of Stay in the Era of COVID-19.
Clinicoecon Outcomes Res;
12: 723-731, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33293840
15.
Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
Am J Manag Care;
26(6): e166-e171, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32549065
16.
Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
Int J Chron Obstruct Pulmon Dis;
15: 2207-2215, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32982213
17.
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Int J Chron Obstruct Pulmon Dis;
15: 2715-2725, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33149569
18.
Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD.
Int J Chron Obstruct Pulmon Dis;
14: 439-446, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30863044
19.
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Int J Chron Obstruct Pulmon Dis;
14: 1721-1737, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31534326
20.
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Int J Chron Obstruct Pulmon Dis;
14: 2047-2060, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31564852